Interv Akut Kardiol. 2014;13(3):143-146

Vernakalant for pharmacological cardioversion of recent-onset atrial fibrillation

Jan Šimek, Tomáš Janota
2. interní klinika a 3. interní klinika VFN, Praha

Vernakalant is atrial selective antiarrhythmic drug developed for rapid intravenous cardioversion of recent-onset atrial fibrillation. Unlike

propaphenone and flecainide, vernakalant can be used in patients with stable coronary artery disease, mild to moderate heart failure

and in patients after recent valvular or coronary artery bypass surgery. The highest conversion rates are systematically observed in the

first 48 hours following the onset of arrhythmia. Unique ability of rapid conversion to sinus rhythm, short elimination half-life, and low

occurrence of serious adverse events are promising for wider use of the drug in a routine clinical practice.

Keywords: atrial fibrillation, antiarrhythmic drugs, vernakalant, pharmacological cardioversion

Published: October 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Šimek J, Janota T. Vernakalant for pharmacological cardioversion of recent-onset atrial fibrillation. Interv Akut Kardiol. 2014;13(3):143-146.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Naccarelli GV, et al. Increasing prevalence of atrial fibrillation and flutter in the United States. The American journal of cardiology 104.11 (2009): 1534-1539. Go to original source... Go to PubMed...
    2. Khan AR, et al., ,Catheter Ablation and Anti-Arrhythmic Drug Therapy as First or Second Line Therapy in the Management of Atrial Fibrillation: A Systematic Review and Meta-Analysis." Circulation: Arrhythmia and Electrophysiology (2014): CIRCEP-114. Go to original source...
    3. Nault I, et al., ,Drugs vs. ablation for the treatment of atrial fibrillation: the evidence supporting catheter ablation." European heart journal (2010): ehq079. Go to original source...
    4. Fiala M. Role katetrové ablace fibrilace síní v prevenci tromboembolické cévní mozkové příhody. Interv Akut Kardiol 2008; 7: 143-146.
    5. Peichl P, Mlčochová H, Čihák R, et al. Selektivní katetrizační ablace fibrilace síní: potenciální komplikace výkonu a možnosti jejich prevence. Interv Akut Kardiol 2008; 7: 226-229.
    6. Relationships Between Sinus Rhythm, Treatment, and Survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. The AFFIRM Investigators, Circulation 2004; 109: 1509-1513. Go to original source... Go to PubMed...
    7. Connolly SJ, Camm AJ, Halperin JL, et al. Dronedarone in High-Risk Permanent Atrial Fibrillation, N Engl J Med 2011; 365: 2268-2276. Go to original source... Go to PubMed...
    8. Alboni, Paolo, et al. Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. New England Journal of Medicine 351.23 (2004): 2384-2391. Go to original source... Go to PubMed...
    9. Pisters R, Nieuwlaat R, Prins MH, Le Heuzey JY, Maggioni AP, Camm AJ, et al. Euro Heart Survey Investigators. Clinical correlates of immediate success and outcome at 1-year follow-up of real-world cardioversion of atrial fibrillation: the Euro Heart Survey. Europace 2012; 14: 666-674. Go to original source... Go to PubMed...
    10. Crijns HJ, Bash LD, Chazelle F, Le Heuzey JY, Lewalter T, Lip GY, et al. RHYTHM-AF: design of an international registryon cardioversion of atrial fibrillation and characteristics of participating centers. BMC Cardiovasc Disord 2012; 12: 85. Go to original source... Go to PubMed...
    11. Roy D, Pratt CM, Torp-Pedersen C, Wyse DG, Toft E, Juul-Moller S, et al. Atrial Arrhythmia Conversion Trial Investigators. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation 2008; 117: 1518-1525. Go to original source... Go to PubMed...
    12. Pratt CM, Roy D, Torp-Pedersen C, Wyse DG, Toft E, Juul-Moller S, et al. Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation. Am J Cardiol 2010; 106: 1277-1283. Go to original source... Go to PubMed...
    13. Stiell IG, Roos JS, Kavanagh KM, Dickinson G. Amulticenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm. AmHeart J 2010; 159: 1095-1101. Go to original source...
    14. Camm AJ, Capucci A, Hohnloser SH, Torp-Pedersen C, Van Gelder IC, Mangal B, et al. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. J Am Coll Cardiol 2011; 57: 313-321. Go to original source... Go to PubMed...
    15. Kowey PR, Dorian P, Mitchell LB, Pratt CM, Roy D, Schwartz PJ, et al. Atrial Arrhythmia Conversion Trial Investigators. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial. Circ Arrhythm Electrophysiol 2009; 2: 652-659. Go to original source... Go to PubMed...
    16. Conde D, et al. Propafenone Versus Vernakalant for Conversion of Recent Onset Atrial Fibrillation. Cardiovascular therapeutics 31.6 (2013): 377-380. Go to original source... Go to PubMed...
    17. Maastricht University Medical Center. Vernakalant Versus Flecainide: Atrial Contractility, In: ClinicalTrials.gov [website on the Internet]. Bethseda, MD: US National Library of Medicine; 2012 [updated July 18, 2012]. Available from: http://clinicaltrials.gov/ct2/show/NCT01646281.
    18. Medical University of Vienna. Vernakalant versus ibutilide in recent-onset atrial fibrillation. In: ClinicalTrials.gov [website on the Internet]. Bethseda, MD: US National Library of Medicine; 2011 [updated February 21, 2012]. Available from: http://clinicaltrials.gov/ct2/show/NCT01447862.
    19. Conde D, et al. Vernakalant versus electrical cardioversion in recent-onset atrial fibrillation. International journal of cardiology 168.4 (2013): 4431-4432. Go to original source... Go to PubMed...
    20. Buccelletti F, Iacomini P, Botta G, Marsiliani D, Carroccia A, Gentiloni S, et al. Efficacy and safetyof vernakalant in recent-onset atrial fibrillation after the European Medicines Agency approval: systematic review and meta-analysis. J Clin Pharmacol 2012; 52: 1872-1878. Go to original source... Go to PubMed...
    21. Bash LD, Buono JL, Davies GM, Martin A, Fahrbach K, Phatak H, et al. Systematic review and meta-analysis of the efficacy of cardioversion by vernakalant and comparators in patients with atrial fibrillation. Cardiovasc Drugs Ther 2012; 26: 167-179. Go to original source... Go to PubMed...
    22. Torp-Pedersen C, Camm AJ, Butterfield NN, Dickinson G, Beatch GN. Vernakalant: conversion of atrial fibrillation in patients with ischemic heart disease. Int J Cardiol 2013; 166: 147-151. Go to original source... Go to PubMed...
    23. Roy D, Rowe BH, Stiell IG, Coutu B, Ip JH, Phaneuf D, et al. CRAFT Investigators. A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation. J Am Coll Cardiol 2004; 44: 2355-2361. Go to original source... Go to PubMed...
    24. Camm AJ, Toft E, Torp-Pedersen C, Vijayaraman P, Juul-Moller S, Ip J, et al. Scene 2 Investigators. Efficacy and safety of vernakalant in patients with atrial flutter: a randomized, double-blind, placebo-controlled trial. Europace 2012; 14: 804-809. Go to original source... Go to PubMed...
    25. Dorian P, Pinter A, Mangat I, Korley V, Cvitkovic SS, Beatch GN. The effect of vernakalant (RSD1235), an investigational antiarrhythmic agent, on atrial electrophysiology in humans. J Cardiovasc Pharmacol 2007; 50: 35-40. Go to original source... Go to PubMed...
    26. Zografos TA, Spiros PK, Apostolos K. Type 1 Brugada pattern exacerbation and 1: 1 atrioventricular conduction induced by vernakalant. Heart Rhythm 11.5 (2014): 895-897. Go to original source... Go to PubMed...
    27. de Riva-Silva M, et al. 1: 1 Atrial Flutter After Vernakalant Administration for Atrial Fibrillation Cardioversion. Revista Espa?ola de Cardiología 65.11 (2012): 1062-1064. Go to original source...
    28. Franzini C, Müller-Burri SA., Shah DC. Atrial flutter with 1: 1 atrioventricular conduction after administration of vernakalant for atrial fibrillation. Europace 2014; 16(1): 3-3. Go to original source... Go to PubMed...
    29. Savelieva I, Graydon R, Camm AJ. Pharmacological cardioversion of atrial fibrillation with vernakalant: evidence in support of the ESC Guidelines. Europace 2014; 16(2): 162-173. Go to original source... Go to PubMed...
    30. Tsuji Y, Dobrev D. Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update. Vascular health and risk management, 2013; 9: 165. Go to original source... Go to PubMed...
    31. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. Focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Europace 2012; 14: 1385-1413. Go to PubMed...
    32. Čihák R, Haman L, Heinc P. Souhrn Aktualizace doporučených postupů ESC pro léčbu fibrilace síní z roku 2012. Cor et Vasa; 54 (2012): 532-541. Go to original source...
    33. Bytešník J. Současné trendy v antiarytmické medikamentózní léčbě fibrilace síní. Interv Akut Kardiol 2009; 8(6): 307-310.
    34. Torp-Pedersen C, Raev DH, Dickinson G, Butterfield NN, Mangal B, Beatch GN. A randomized, placebo-controlled study of vernakalant (oral) for the prevention of atrial fibrillation recurrence after cardioversion. Cir Arrhythm Electrophysiol. 2011; 4(5): 637-643. Go to original source... Go to PubMed...
    35. Táborský M, Heinc P. Vernakalant - antiarytmikum nové generace pro akutní verzi fibrilace síní. Farmakoterapie 2012; 8(1): 42-48.

    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.